supported by the National Key R&D Program of China(2019YFA0906003);the National Natural Science Foundation of China(32000989);China Postdoctoral Science Foundation Grant(2020M682911 and 2020M670051ZX);Guangdong Special Support Program(2021JC06Y578);the Shenzhen Municipal Government of China(JCYJ20200109120016553,CJGJZD20200617102403009,and RCBS20210706092256081);the Sanming Project of Shenzhen Health and Family Planning Commission(SZSM202011017);Shenzhen Institute of Synthetic Biology Scientific Research Program(ZTXM20214005);the Shenzhen High-level Hospital Construction Fund。
supported by NSFC grant 81571080(Zhanfeng Jia,China),81872848(Wei Zhang,China);the Central Government Guiding Local Funding Project for Scientific and Technological Development 206Z7703G(Zhanfeng Jia,China);Key Project and Cultivation Project of Precision Medicine Joint Fund of Natural Science Foundation of Hebei Province H2021206406(Zhanfeng Jia,China),H2022206211(Wei Zhang,China)and H2020206165(Zhanfeng Jia,China);Science and Technology Project of Hebei Education Department ZD2020107(Zhanfeng Jia,China);Science Fund for Creative Research Groups of Natural Science Foundation of Hebei Province H2020206474,China.
Vincristine,a widely used chemotherapeutic agent for treating different cancer,often induces severe peripheral neuropathic pain.A common symptom of vincristine-induced peripheral neuropathic pain is mechanical allodyn...
Vincristine is a chemotherapy drug belonging to the group of Vinca alkaloids which also includes vinblastine and vindesine. It is used in hematological malignancies and solid tumors. The Vinca alkaloids are neurotoxic...
supported by Suzhou Science and Technology Development Plan (SKJYD2021047);the Fundation of Suzhou Kowloon Hospital (SZJL202111 and SZJL202104)
Objective:To explore the mechanism of drug resistance in acute lymphoblastic leukemia and the anti-tumor effect of combination therapy of dehydroabietic acid and vincristine against acute lymphoblastic leukemia cells....
In the original version of this article on p 122, two inappropriate images were placed in B and C of Fig. 1, which didn’t represent the group of FA-PEG-LS and PEG-LS/VCR. In the revised graphic provided below, the ap...
BACKGROUND B-cell lymphoma,unclassifiable,with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma(BCLu-DLBCL/cHL),also referred to as gray zone lymphoma(GZL),is known to share f...
The means of cancer treatment and the understanding of chemotherapeutic drugs have made continuous progress in the past few decades. Chemotherapy is a basic and widely useful therapeutic method, and various therapeuti...
supported by the sponsor Shenzhen Chipscreen Biosciences Co.,LTD.;by grants from the China National Major Project for New Drug Innovation(No.2017ZX09304015);the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)(No.2016-I2M-1-001)。
Objective:Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma(PTCL).This phase 1 b study evaluated the safety,pharmacokinetics,and prelim...
Primary gastric lymphomas(PGLs)are distinct lymphoproliferative neoplasms described as heterogeneous entities clinically and molecularly.Their main histological types are diffuse large B-cell lymphoma(DLBCL)or mucosaa...
Supported by the Soonchunhyang University Research Fund,No.20200011.
BACKGROUND Choriocarcinoma is an infrequent entity and the most aggressive subtype of germcell tumors.Because of early metastatic spread and rapid disease progression,choriocarcinoma patients display poor prognosis.Al...